Vira Pravosud1, David M Mannino1,2, Delia Prieto2, Quan Zhang3, Radmila Choate1,2, Elisha Malanga2, Timothy R Aksamit4. 1. College of Public Health, University of Kentucky, Lexington, Kentucky, United States. 2. COPD Foundation, Washington, DC, United States. 3. School of Public Health, Rutgers University, Piscataway, New Jersey, United States. 4. Pulmonary Disease and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, United States.
Abstract
PURPOSE: Respiratory diseases caused by nontuberculous mycobacteria (NTM) have become a significant concern for patients and health care providers. We aimed to compare symptoms experienced during the 2 week period, at a single point in time, by patients with NTM lung disease (NTMLD) who were currently on any medication to treat their NTMLD versus those not on any therapies. METHODS: We analyzed responses to a "Burden of NTM Survey" developed by the COPD Foundation. The study population included 266 individuals with NTMLD. Using adjusted penalized logistic regression models, we determined associations between the self-reported symptoms and the use of any medication to treat NTMLD. RESULTS: Based on available data, most respondents were aged 50 and older (95.1%), of female gender (93.1%), and had been living with NTMLD for more than 5 years (55.7%). Many respondents reported symptoms that bother them very often or daily. After adjustment for age and gender, duration of living with NTMLD, and other respiratory illnesses, patients on medication had significantly larger odds of reporting difficulty in walking 500 meters without stopping, difficulty in interacting with others, fatigue or lack of energy, feelings of sadness or depression related to illness, and shortness of breath, wheezing or other difficulties. CONCLUSION: In this study, patients currently on any medication to treat their NTMLD reported more symptoms associated with their NTMLD. Further investigations are needed to explore whether increased symptoms are related to differences in disease severity and/or medication effects. JCOPDF
PURPOSE: Respiratory diseases caused by nontuberculous mycobacteria (NTM) have become a significant concern for patients and health care providers. We aimed to compare symptoms experienced during the 2 week period, at a single point in time, by patients with NTM lung disease (NTMLD) who were currently on any medication to treat their NTMLD versus those not on any therapies. METHODS: We analyzed responses to a "Burden of NTM Survey" developed by the COPD Foundation. The study population included 266 individuals with NTMLD. Using adjusted penalized logistic regression models, we determined associations between the self-reported symptoms and the use of any medication to treat NTMLD. RESULTS: Based on available data, most respondents were aged 50 and older (95.1%), of female gender (93.1%), and had been living with NTMLD for more than 5 years (55.7%). Many respondents reported symptoms that bother them very often or daily. After adjustment for age and gender, duration of living with NTMLD, and other respiratory illnesses, patients on medication had significantly larger odds of reporting difficulty in walking 500 meters without stopping, difficulty in interacting with others, fatigue or lack of energy, feelings of sadness or depression related to illness, and shortness of breath, wheezing or other difficulties. CONCLUSION: In this study, patients currently on any medication to treat their NTMLD reported more symptoms associated with their NTMLD. Further investigations are needed to explore whether increased symptoms are related to differences in disease severity and/or medication effects. JCOPDF
Authors: Jennifer Adjemian; Kenneth N Olivier; Amy E Seitz; Joseph O Falkinham; Steven M Holland; D Rebecca Prevots Journal: Am J Respir Crit Care Med Date: 2012-07-05 Impact factor: 21.405
Authors: Alexandra L Quittner; Anne E O'Donnell; Matthias A Salathe; Sandra A Lewis; Xiaoming Li; A Bruce Montgomery; Thomas G O'Riordan; Alan F Barker Journal: Thorax Date: 2014-10-16 Impact factor: 9.139
Authors: J Min; J Park; Y J Lee; S J Kim; J S Park; Y-J Cho; H I Yoon; C-T Lee; J H Lee Journal: Int J Tuberc Lung Dis Date: 2015-10 Impact factor: 2.373